Microbot Medical

Microbot Medical Inc. is a clinical-stage medical device company developing robotic technologies for minimally invasive endovascular procedures. The company's lead product, the LIBERTY® Robotic System, is designed as a single-use, remote-operated robotic platform for vascular catheterization that does not require fixed capital equipment or a dedicated interventional suite.

The LIBERTY system aims to address several challenges in interventional procedures, including the physical strain on physicians from manual catheter manipulation, radiation exposure during fluoroscopy-guided procedures and the high capital costs associated with existing robotic surgical platforms. By offering a compact, disposable robotic device, Microbot targets a broader range of clinical settings than traditional fixed robotic systems.

Microbot Medical is conducting clinical evaluations of the LIBERTY system and has submitted it for regulatory review with the U.S. Food and Drug Administration. The company's technology platform draws on expertise in micro-robotics and miniaturized mechanical systems, with potential applications across multiple interventional specialties. Microbot trades on the Nasdaq under the ticker symbol MBOT.